Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

206.92 USD +6.38 (+3.18%)
Official Closing Price Updated: 7:59 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,876,100
Open 201.13
Bid (Size) 207.10 (1)
Ask (Size) 207.60 (1)
Prev. Close 200.54
Today's Range 200.88 - 207.67
52wk Range 117.06 - 218.00
Shares Outstanding 1,085,430,420
Dividend Yield 1.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
CHMP has completed a review of available data for both antibodies for the treatment of confirmed COVID-19 
From PR Newswire
Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data from the pirtobrutinib (previously referred to as... 
From PR Newswire

Performance

YTD
+25.03%
+25.03%
1 Month
+2.63%
+2.63%
3 Month
+40.36%
+40.36%
6 Month
+38.58%
+38.58%
1 Year
+46.27%
+46.27%

More News

Read More
Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
From PR Newswire
Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial
From PR Newswire
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
From PR Newswire
Should Investors Be Watching These Top Health Care Stocks Right Now?
Tags Market News
From StockMarket.com
U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy
From GlobeNewswire News Releases
EMA's Medicinal Committee Backs Eli Lilly's COVID-19 Antibody Therapy
Tags Covid/19 Biotech Market News
From Benzinga
Eli Lilly's Tirzepatide Tops Novo's Semaglutide In Late-Stage Diabetes Study
Tags LLY General Diabetes
From Benzinga
Eli Lilly/Incyte's Baricitinib Shows Benefit In Patchy Hair Loss Disorder
Tags News Health Care LLY
From Benzinga
Vir Stock Craters On Weak Data For GSK-Partnered Covid Treatment
From Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.